Diferencia entre revisiones de «Enoxaparin»

(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template))
Línea 48: Línea 48:
*Excretion: urine
*Excretion: urine
*Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III
*Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III
==Indications by Condition==
''The following table is automatically generated from disease/condition pages across WikEM.''
{{#ask:[[Has DrugName::Enoxaparin]]
|?Has Indication=Indication
|?Has Dose=Dose
|?Has Context=Context
|?Has Route=Route
|?Has Population=Population
|format=broadtable
|headers=plain
|link=subject
|sort=Has Indication
|limit=50
}}


==See Also==
==See Also==

Revisión del 16:44 20 mar 2026

General

Adult Dosing

Therapeutic anticoagulation (e.g. treating DVT/PE, unstable angina)

  • 1mg/kg SC q12h

Chemical Prophylaxis of VTE

  • Lovenox 30mg SubQ q12 hrs (if Cr Clearance > 30)
    • Check Anti-Xa level every week EXACTLY 4 hours after 3rd dose of lovenox
      • prophylactic goal: 0.2-0.6
      • therapeutic goal: 0.6-1.2
  • Recheck AntiXa level after each 3rd dose if dose is changed until you are at goal
  • Recheck level every week (usually qMonday) for all patients
  • If renal dysfunction order heparin 5000 Units SubQ q8 hrs (search “SURG DVT/VTE prophylaxis” order set)

Pediatric Dosing

Off-label

  • DVT prophylaxis:
    • <2 months: 0.75 mg/kg SC q12hr
    • ≥2 months: 0.5 mg/kg SC q12h
  • Therapeutic anticoagulation:
    • <2 months: 1.5 mg/kg SC q12hr
    • ≥2 months: 1 mg/kg SC q12hr

Special Populations

  • Pregnancy Rating: B
  • Lactation: Unknown risk
  • Renal Dosing
    • Renal impairment (creatinine clearance <30)
      • Use 50% of usual dose or use UFH instead
  • Hepatic Dosing: not established
  • Obesity
    • Weight-based dosing safe up to 190kg (no data available thereafter)

Indications

Contraindications

  • Allergy to class/drug

Adverse Reactions

  • Bleeding
  • Pruritus
  • Local skin reaction

Pharmacology

  • Half-life: 4.5h
  • Metabolism: hepatic
  • Excretion: urine
  • Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III


Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

 IndicationDoseContextRoutePopulation
Non-ST-elevation myocardial infarction#Enoxaparin Antithrombotic; preferred over UFH unless CABG within 24hr AdultNon-ST-elevation myocardial infarction1mg/kg BIDAntithrombotic; preferred over UFH unless CABG within 24hrSCAdult
Pulmonary embolism#Enoxaparin Anticoagulation (1st line, LMWH) AdultPulmonary embolism1 mg/kg SC q12hAnticoagulation (1st line, LMWH)SCAdult
ST-segment elevation myocardial infarction#Enoxaparin Anticoagulation (LMWH) AdultST-segment elevation myocardial infarction30 mg IV bolus, then 1 mg/kg SC q12h (<75yo); 0.75 mg/kg SC q12h (≥75yo); 1 mg/kg SC daily (CrCl <30)Anticoagulation (LMWH)IV/SCAdult
Unstable angina#Enoxaparin Antithrombotic, alternative to UFH AdultUnstable angina1mg/kg SC q12hrAntithrombotic, alternative to UFHSCAdult

See Also

References